Product Description

CDK1/CyclinA2 is a serine/threonine kinase complex composed of the catalytic subunit CDK1 (cyclin-dependent kinase 1, also known as CDC2) and the regulatory subunit Cyclin A2, which plays a pivotal role in cell cycle progression, specifically driving the transition from G2 phase to M phase and facilitating mitotic entry. The CDK1/CyclinA2 complex phosphorylates a wide range of substrates involved in cytoskeletal reorganization, chromosome condensation, nuclear envelope breakdown, and spindle assembly. Beyond its essential physiological functions in cell division, dysregulation of CDK1/CyclinA2 signaling—including overexpression, aberrant activation, and altered complex formation—is frequently observed in various human cancers, such as breast, lung, liver, and colorectal cancer, contributing to uncontrolled proliferation, genomic instability, and poor prognosis. These features have established CDK1/CyclinA2 as a highly validated target for cancer therapy and drug discovery.

Screeningbio’s CDK1/CyclinA2 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CDK1/CyclinA2 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).

This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.

The assay is performed in two distinct steps:

1. Kinase Reaction: CDK1/CyclinA2 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.

2. ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.

3. Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.

The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CDK1/CyclinA2 kinase.